跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
LUXIQ
Authorized
STANDARD
LUXIQ
MAYNE PHARMA INC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
185adc2db50f6848
Company
MAYNE PHARMA INC
Type
Standard
Approval Details
Approval Id
185adc2db50f6848
Drug Approval Canada Name
LUXIQ
Product Name
LUXIQ
Status
Cancelled Post Market
Status Date
2020-01-09
Original Market Date
2012-02-10
Din
02366924
Drug Class
Human
Dosage Form
Aerosol, Foam
Route Of Administration
Topical
Schedule
Prescription
Ahfs
84:06.00
Atc Original
D07AC01 BETAMETHASONE
Atc Name
d 07 ac 01
Aig Number
0106302004
Company Name
MAYNE PHARMA INC
Company Address
1240 Sugg Parkway, Greenville, North Carolina, United States, 27834
Company Detail Path
/organization/mayne-pharma-inc
Company Information
Pharmaceutical Company Name
MAYNE PHARMA INC
Country Name
Spain
Province Name
Madrid
City Name
madrid,madrid,country_es
Address
CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Active Ingredients
BETAMETHASONE VALERATE
0.12 %
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
185adc2db50f6848
Type
Standard
Back to Health Canada Approvals
LUXIQ - Health Canada Drug Approval Details